Johnson & Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

The pharmaceutical and medtech giant reported sales of $23.99 billion, up 6.8% year over year and beating the consensus of $23.74 billion. Operational growth was 5.4%, and adjusted operational growth was 4.4%.

Innovative Medicine sales increased 6.8% or 5.3% operationally to $15.56 billion.

Also Read: FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

Growth was driven by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), Rybrevant/Lazcluze in oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, and Spravato (esketamine) in neuroscience.

Growth was partially offset by an approximate (1,070) basis points impact from Stelara in Immunology and Imbruvica in Oncology.

Cancer sales increased to $6.53 billion, up 21.3% (+19.2% operational). Immunology sales declined to $4.17 ...